The data continue to show that there are no signs of a possible fatigue in the materials used. Peter Gabriel may find it difficult to be quoted properly. For the most recent CI512 of the cochlear nucleus implant exist with the presented report data from 18 months. Assign a 99.96% reliability rate. A significant reduction of the failure rate in CI powered children is also striking. This is due to the improved properties compared with impact. Through the complete documentation on now 23 years and over 168,000 registered implants we offer maximum security”, so Robert finally Pera.

Each still so rare failure of any system analyzes us in a complex process, constantly expanding the reliability. In addition cochlear granted to a ten-year guarantee, which covers even a failure due to external agents for every implant.” Editorial Note: the company cochlear is global market leader in the development and manufacture of cochlear implants (CI). The breakthrough technology of this CI systems allows to listen to children and adults with profound and adjacent to deafness hearing loss. The company was founded in 1982, to the research of Australian Medicine Professor Graeme Clark, the inventor of the multiple-channel cochlear implant, to continue and to market worldwide. Today, more than 230,000 people in over 100 countries hearing solutions carry cochlear. The company employs currently over 2,000 people.

The German branch of cochlear is Hanover. For more information see. The cochlear implant (CI) is inserted under the skin of the patients, ranging in the inner ear. It transforms spoken words and other acoustic signals into electrical impulses. The auditory nerve is stimulated by these impulses, which is located in the cochlea, the so called cochlear. Each CI also include the language processor that is worn like a hearing aid behind the ear, as well as the emitter.

Therefore, the number of hospitals as a precaution offered protection from adhesions at Kaiser cut maternity is growing. Best to prevent adhesions by you actively prevents them from the outset. Have they once trained themselves, they can cause complications and must be often surgically removed. This means that the use of an adhesion barrier is already at the first caesarean section”, explains Mr. Sliwinskij, document doctor in the Marienhospital Darmstadt. Scientific studies confirm that the risk of adhesions is reduced significantly: only about seven percent of Cesarean section patients have to use prophylaxis adhesions on without protection it is nearly half. Sliwinskij: adhesion barriers come benefit our patients, that these otherwise under InterGrowth-related pain can suffer. Also complicate existing adhesions reoperation often and can be cause for a subsequent infertility of patients.” How are adhesions? Causes and consequences at the Emperor cut maternity are severed as in all surgical interventions of human tissues.

Adhesions between internal organs and tissues can develop in the course of the body’s own healing process by an excessive wound healing response. The patients do not feel these adhesions initially often. In many cases, they cause no difficulty even years after surgery. If the adhesions but strengthen in the course of time and impede the movement of organs or they constrict even, can prepare the affected huge problems: the complaints range from chronic abdominal pain of intestinal narrowing to an infertility caused by adhesions. Also, adhesions to complications in future emperor cutting childbirth can and do other surgical procedures. Not infrequently they entail operative treatment often only years later. Genzyme provides patients and interested under the Internet address information on the topics of caesarean section and protection from adhesions. In addition also a free service available hotline.

Questions can be via email at. About Genzyme’s Genzyme headquartered in Cambridge, Massachusetts (United States) among the world’s leading biotechnology companies. Since its founding in 1981, Genzyme from a small start-up has developed to one of the most successful companies in the biotechnology sector with more than 12,000 employees in over 40 countries. In the last two decades, Genzyme has brought a variety of breakthrough therapies for some not previously treatable diseases on the market, to help patients in approximately 100 countries. The biotechnology company focused in his Research the area of rare diseases (orphan diseases) and there is the focus on the Lysosomal Storage diseases. In addition, Nephrology and cardiovascular diseases, transplantation medicine and the fields of autoimmune diseases, oncology and malignant thyroid disease and orthopedic applications belong to the research and the field of activity of the company. On the German site in Neu-Isenburg, over 180 employees perceive mainly sales activities and pursue an ethically responsible and service-oriented cooperation with medical professionals and patients.

Early application benefit such people who are so on the way to the diabetes, but have still not manifest disease, the best of the natural substances. This applies in particular for men over 45 and women over 55 years of age, who are vulnerable to diabetes and CHD, so atherosclerosis, heart attack and stroke in corresponding risk situation. Lives in Germany about any third party on this risk threshold of obesity (waist circumference), slightly elevated blood sugar, slightly elevated cholesterol, slightly elevated total lipids and elevated blood pressure. What can you do to defuse the ticking time bomb, to reduce the diabetes and heart attack risk, and to strengthen the health? It should be the number Risk factors are reduced. One of the most important measures in this direction is the risk factor to get obesity under control. This measure alone can reduce the increased risk of disease by around 20%, but alone is not sufficient. To do this, other risk factors need to be tackled. The gentle natural substances with proven efficacy can help here.

Risk factors such as cholesterol, blood fats and high blood sugar can be tackled today on evidence-based based aqueous cinnamon extract with the natural fiber of glucomannan. The DiVitum product aimed at people who want to reduce their specific risk for diabetes, heart attack and stroke by controlling important risk factors and promote their health. . The special composition and dosage of DiVitum (PZN 4604195) is based on study results. Therefore, it should be replaced at the pharmacy not against other products, even if they may seem similar. DiVitum is available in pharmacies, selected health centers and direct available at Navitum Pharma. Shipping is always free of charge to pharmacies and consumers. Cheap packs for 3 months (PZN 0247798) and 6 months (PZN 0250079) are on the market.

Source: Shen Y, et al. Biosci Biotechnol Biochem. 2010;74(12):2418-25. epub 2010 Dec 7 Roussel, A.M. et al. Journal of the American College of nutrition, vol. 28, no.. 1: 16-21 (2009); Hlebowitz J. et al. Am J Clin Nutr. 2007; 85(6): 1552-6; Pham a.q. et al. pharmacotherapy 2007; 27(4) 595-9 contact: Navitum Pharma GmbH Dr. Gerhard Klages at the water tower 29 65207 Wiesbaden Tel: 0611-58939458 FAX: 0611-9505753 E-Mail: Web:

Proteins from semen as a potential source of information provide information. Prostate cancer is the second most common cancer of men worldwide. But long since not all prostate cancer is associated with a poor prognosis, which requires immediate intervention. There is, therefore, a major challenge to the diagnosis of prostate cancer, to distinguish between aggressive non-aggressive tumors. Currently, but still no procedure provides the necessary security. Scientists of the Urology Clinic of the University Hospital Leipzig AoR (www.urologie.uniklinikum-leipzig.de) have identified ejaculate as a potential source of information for detecting aggressive prostate tumors in cooperation with the Hanoverian biotechnology company of mosaiques diagnostics (www.mosaiques-diagnostics.com). Now, the results of their study were published in the current issue of the prestigious journal PLoS one: article/info%3Adoi%2F10.1371%2Fjournal.pone.0067514 In the study were using a special protein-analysis of ejaculate first specific markers for the diagnosis of Prostate cancer are identified. In a further step, the scientists succeeded in identifying 11 protein marker for the first time allow a distinction between the aggressive form of prostate cancer and a slowly growing tumor.

With a sensitivity of 80% and a specificity of 82%, protein analysis in the ejaculate allows a very high reliability in the differentiation of the tumor stage. Although in this respect still no real alternative to the tissue extraction from the prostate, the results of our study are very promising and could enable also a clear recommendation of the therapy in the future in addition to a specific diagnosis”, summarizes Dr. Neuhaus the results of the study. So far a combination of PSA test (prostate specific antigen), palpation, number of positive samples and the determination of the so-called Gleason value was used after the removal of tissue, to identify aggressive prostate tumors. However, slightly elevated PSA levels between 4 and 10 ng/ml and moderate show the majority of the discovered tumors Gleason values between 6 and 7, which greatly complicates a treatment decision. Tissue sampling be carried out to determine the value of the Gleason invasive, ejaculate, however, can be easily and without intervening measures to win. A clear added value on our way to more and more patient-friendly Diagnostics”, explains Dr. Eric Schiffer mosaiques Diagnostics.

Reference Neuhaus J, Schiffer E, Wilcke P, Bauer HW, Leung H, Siwy Ulrici W, p U, J, LC, Horn Santana J seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease PLoS ONE 8(6): e67514. DOI:10.1371/journal.Pone.0067514 about mosaiques diagnostics: A leading biotech company in the area of clinical analysis of protein in the urine (UPA), mosaiques diagnostics recognized cooperation partner of renowned university hospitals all over the world is. The UPA test is subject to over 60 multicenter studies, including several EU consortia. 155 Publications in high-ranking, international journals have appeared to a few years. Under the diagnostic tests for different diseases on the market the brand name DiPat (www.diapat.de) are available. They are suitable in particular for the early detection of chronic kidney disease (CKD), such as the diabetic nephropathy (DN), as well as for coronary heart disease (CHD). Thus, the protein analysis is predestined to implement evidence-based, personalized treatments in patients with diabetes mellitus effectively.

Proteins from semen as a potential source of information provide information. Prostate cancer is the second most common cancer of men worldwide. But long since not all prostate cancer is associated with a poor prognosis, which requires immediate intervention. There is, therefore, a major challenge to the diagnosis of prostate cancer, to distinguish between aggressive non-aggressive tumors. Currently, but still no procedure provides the necessary security. Scientists of the Urology Clinic of the University Hospital Leipzig AoR (www.urologie.uniklinikum-leipzig.de) have identified ejaculate as a potential source of information for detecting aggressive prostate tumors in cooperation with the Hanoverian biotechnology company of mosaiques diagnostics (www.mosaiques-diagnostics.com).

Now, the results of their study were published in the current issue of the prestigious journal PLoS one: article/info%3Adoi%2F10.1371%2Fjournal.pone.0067514 In the study were using a special protein-analysis of ejaculate first specific markers for the diagnosis of Prostate cancer are identified. In a further step, the scientists succeeded in identifying 11 protein marker for the first time allow a distinction between the aggressive form of prostate cancer and a slowly growing tumor. With a sensitivity of 80% and a specificity of 82%, protein analysis in the ejaculate allows a very high reliability in the differentiation of the tumor stage. Although in this respect still no real alternative to the tissue extraction from the prostate, the results of our study are very promising and could enable also a clear recommendation of the therapy in the future in addition to a specific diagnosis”, summarizes Dr. Neuhaus the results of the study. So far a combination of PSA test (prostate specific antigen), palpation, number of positive samples and the determination of the so-called Gleason value was used after the removal of tissue, to identify aggressive prostate tumors. However, slightly elevated PSA levels between 4 and 10 ng/ml and moderate show the majority of the discovered tumors Gleason values between 6 and 7, which greatly complicates a treatment decision.

Tissue sampling be carried out to determine the value of the Gleason invasive, ejaculate, however, can be easily and without intervening measures to win. A clear added value on our way to more and more patient-friendly Diagnostics”, explains Dr. Eric Schiffer mosaiques Diagnostics. Reference Neuhaus J, Schiffer E, Wilcke P, Bauer HW, Leung H, Siwy Ulrici W, p U, J, LC, Horn Santana J seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease PLoS ONE 8(6): e67514. DOI:10.1371/journal.Pone.0067514 about mosaiques diagnostics: A leading biotech company in the area of clinical analysis of protein in the urine (UPA), mosaiques diagnostics recognized cooperation partner of renowned university hospitals all over the world is. The UPA test is subject to over 60 multicenter studies, including several EU consortia. 155 Publications in high-ranking, international journals have appeared to a few years. Under the diagnostic tests for different diseases on the market the brand name DiPat (www.diapat.de) are available. They are suitable in particular for the early detection of chronic kidney disease (CKD), such as the diabetic nephropathy (DN), as well as for coronary heart disease (CHD). Thus, the protein analysis is predestined to implement evidence-based, personalized treatments in patients with diabetes mellitus effectively. More tests for the early detection of stenosis of renal pelvis outlet in newborn (UPJO), acute Graft-versus-host disease (GvHD) in allogeneic stem cell transplantation (SCT) and bile duct cancer, bladder and prostate cancer are also already available.